ReviewMediterranean journal of rheumatology2017
Regulatory B cells in autoimmune rheumatic diseases.
Review in Mediterranean journal of rheumatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 12 citations in OpenAlex.
- Review
- An Observational Case-Control Study of the Anti-Inflammatory Effects of Bromelain on Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus.Mediterranean journal of rheumatology · 2026Article
- Roles of immune cell metabolism in rheumatoid arthritis.Frontiers in immunology · 2026Review
- Chimeric Antigen Receptor T Cell Immunotherapy for Autoimmune Rheumatic Disorders: Where Are We Now?Cells · 2025Review
- Common pathological mechanisms and therapeutic strategies in primary Sjogren's syndrome and primary biliary cholangitis: from tissue immune microenvironment to targeted therapy.Frontiers in immunology · 2025Review
- Fly Me to the Immune: Immunonutrition in Rheumatic Diseases.Mediterranean journal of rheumatology · 2023Article
- B Cells in Breast Cancer Pathology.Cancers · 2023Review
- Mediterranean Journal of Rheumatology June 2017 Highlights.Mediterranean journal of rheumatology · 2017Article
- A Case Report of Adjuvant Molecular Hydrogen Therapy in Refractory Rheumatoid Arthritis With Atlantoaxial Subluxation.In vivo (Athens, Greece)Article
- Molecular Hydrogen Therapy in Rheumatoid Arthritis: A Case Report on the Amelioration of Methotrexate-induced Myelosuppression and Immune Modulation.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRegulatory B cells (regulatory B cells, Breg cells) in recent years have been shown to be important immunoregulatory factors.
aimTo review the role of Breg cells in autoimmune rheumatic diseases.
methodsThis descriptional review was carried out after research on PubMed using the keywords "Bregs and rheumatoid arthritis", "systemic lupus erythematosus", "Sjögren's syndrome", "systemic sclerosis", "vasculitis", and "dermatomyositis".
resultsBreg cells have an inhibitory effect on pro-inflammatory Th1 and Th17 cells and prevent the development of autoimmune diseases. Breg cells mediate their effects through interleukin-10 (IL-10, IL-10+Breg cells), but recently other Breg cells have been recognized that mediate their effects through IL-35 (IL-35+Breg cells), or through transforming growth factor-β (TGFβ, TGFβ+Breg cells). In experimental models of autoimmune diseases, Breg cells are decreased, and when expanded ex vivo and re-infused back into animals, they ameliorate disease. In humans, IL-10+Breg cells are decreased in active autoimmune diseases, such as rheumatoid arthritis, ANCA-associated vasculitis, and systemic sclerosis, and may increase to normal levels in disease remission.
conclusionsThe deficiency of IL-10+Breg cells during active autoimmune rheumatic disease suggests that Breg cells may be used as biomarkers and be a possible therapeutic target in these diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.